| Fund ID | 805-2794267530 |
| Fund type | Private Equity Fund |
| 3(c)(1) exclusion | Yes |
| 3(c)(7) exclusion | Yes |
| Master fund | No |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | Yes |
| Sales limited to qualified investors | Yes |
| % of assets independently valued | 0% |
| Owned by the adviser or related persons | 1% |
| Owned by funds of funds | 56% |
| Owned by non-U.S. persons | 41% |
| Fund | Type | Gross assets |
|---|---|---|
| Carlyle Partners VII | Private Equity | $22.76B |
| Carlyle Partners VIII | Private Equity | $12.08B |
| Carlyle Property Investors, L.P. | Real Estate | $7.6B |
Abingworth Clinical Co-Development Fund 2 LP reports $206.7 million in gross assets, among the top 30% of private funds by size.
The stated minimum investment is $60,000.
Abingworth Clinical Co-Development Fund 2 LP is managed by Carlyle Investment Management L.L.C.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.